Primary Mediastinal (Thymic) Large B-Cell Lymphoma · line 2 · R-ICE salvage with autoSCT consolidation (relapsed/refractory PMBCL)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-R-ICE-PMBCL |
| ID | IND-PMBCL-2L-RICE-AUTOSCT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-PMBCL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
Standard-track 2L for transplant-eligible r/r PMBCL. For transplant-ineligible: pembrolizumab (KEYNOTE-170). CAR-T alternative for chemorefractory or post-autoSCT relapse — UA access via international referral only.
Used By
Algorithms
ALGO-PMBCL-2L- ALGO-PMBCL-2L